Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.
| Revenue (TTM) | $3.10B |
| Gross Profit (TTM) | $2.12B |
| EBITDA | $945.06M |
| Operating Margin | 21.30% |
| Return on Equity | 13.30% |
| Return on Assets | 8.18% |
| Revenue/Share (TTM) | $22.99 |
| Book Value | $34.88 |
| Price-to-Book | 2.25 |
| Price-to-Sales (TTM) | 3.53 |
| EV/Revenue | 3.26 |
| EV/EBITDA | 11.46 |
| Quarterly Earnings Growth (YoY) | 66.70% |
| Quarterly Revenue Growth (YoY) | 27.00% |
| Shares Outstanding | $113.31M |
| Float | $111.70M |
| % Insiders | 0.73% |
| % Institutions | 102.03% |
Volatility is currently contracting
GMED is gaining share in musculoskeletal solutions with strong implant and trauma growth, backed by a debt-free balance sheet despite cost and FX pressures.
When investors think of the health care sector, most imagine the stability of pharmaceutical giants or the high-risk/high-reward profile of up-and-coming clinical stage drug developers. Medical device companies operate within a unique ecosystem and are often easy to overlook.
Globus Medical's 43.6% one-year rally is fueled by strong growth across both business segments, rising technology adoption and a debt-free balance sheet.
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Globus Medical, Inc. (NYSE: GMED) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
AUDUBON, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30, 2026 after the market close on Thursday, August 6, 2026.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Globus Medical or Medtronic? See why Globus Medical's stronger growth, innovation and analyst upside may give it the edge despite a richer valuation.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GMED and any ticker you trade — then tracks every position and per-strategy win rate.
